Day One Biopharmaceuticals Inc
$0
0%
2026-07-22 07:32:00
dayonebio.com
NMS: DAWN
Explore Day One Biopharmaceuticals Inc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.22 B
Current Price
$0
52W High / Low
$21.53 / $5.63
Stock P/E
—
Book Value
$4.28
Dividend Yield
—
ROCE
-28.56%
ROE
-23.43%
Face Value
—
EPS
$-1.04
Exp Qtr EPS
—
Sector
Healthcare
DAWN — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $675.19 | 15.81 | $69.94 B | 0.56% | 10.23% | 14.32% | $821.11 / $541 | $295.71 |
| 3. | Revolution Medicines, Inc. | $183.29 | — | $38.94 B | — | -57.28% | -54.06% | $193.82 / $34 | $8.28 |
| 4. | Alnylam Pharmaceuticals, Inc. | $271.37 | 62.78 | $36.24 B | — | 14.33% | 98.29% | $495.55 / $266.27 | $5.96 |
| 5. | Roivant Sciences Ltd. | $34.96 | — | $33.71 B | — | -21.06% | -6.85% | $37 / $10.9 | $6.28 |
| 6. | Royalty Pharma plc | $58.42 | 40.45 | $33.47 B | 1.61% | 8.21% | 12.67% | $59.44 / $34.08 | $11.22 |
| 7. | Moderna, Inc. | $59.66 | — | $23.63 B | — | -29.7% | -36.73% | $85.6 / $22.28 | $21.95 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 53.72 M | 39.8 M | 33.91 M | 30.76 M | 29.21 M | — |
| Operating Profit | -27.46 M | -24.25 M | -34.97 M | -41.07 M | -65.33 M | — |
| Net Profit | -21.28 M | -19.73 M | -30.32 M | -36 M | -65.71 M | — |
| EPS in Rs | -0.21 | -0.19 | -0.29 | -0.35 | -0.64 | 0.38 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 158.18 M | 131.16 M | 0 M | 0 M |
| Operating Profit | -127.75 M | -217.27 M | -206.06 M | -146.91 M |
| Net Profit | -107.32 M | -95.5 M | -188.92 M | -142.18 M |
| EPS in Rs | -1.04 | -0.92 | -1.83 | -1.38 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 507.83 M | 582.79 M | 376.05 M | 349.06 M |
| Total Liabilities | 66.67 M | 80.04 M | 29.51 M | 17.02 M |
| Equity | 441.16 M | 502.75 M | 346.54 M | 332.04 M |
| Current Assets | 485.1 M | 562.33 M | 375.27 M | 347.87 M |
| Current Liabilities | 60.52 M | 73.45 M | 29.51 M | 16.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -103.76 M | -78.11 M | -146.85 M | -109.87 M |
| Investing CF | 174.65 M | -230.99 M | 128.38 M | -255.07 M |
| Financing CF | 1.22 M | 203.29 M | 164 M | 165.9 M |
| Free CF | -107.58 M | -152.38 M | -150.08 M | -109.9 M |
| Capex | -3.82 M | -74.27 M | -3.22 M | -0.03 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 49.45% | -32.87% | — | — |
| Profit Margin % | -72.81% | — | — | — |
| Operating Margin % | -165.65% | — | — | — |
| Gross Margin % | 95.98% | — | — | — |
| EBITDA Margin % | -164.1% | — | — | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
No stock split history available.